Reviewing Raia Drogasil (RADLY) and Its Peers

Raia Drogasil (OTCMKTS:RADLY – Get Free Report) is one of 150 publicly-traded companies in the “Consumer Staples Distribution & Retail” industry, but how does it contrast to its peers? We will compare Raia Drogasil to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, dividends, institutional ownership and valuation.

Insider & Institutional Ownership

45.0% of shares of all “Consumer Staples Distribution & Retail” companies are owned by institutional investors. 19.7% of shares of all “Consumer Staples Distribution & Retail” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Raia Drogasil and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Raia Drogasil 2.89% 20.61% 6.02%
Raia Drogasil Competitors -7.52% 3.77% 3.02%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Raia Drogasil and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Raia Drogasil 0 1 1 0 2.50
Raia Drogasil Competitors 2253 8318 10117 459 2.42

Raia Drogasil presently has a consensus target price of $5.20, indicating a potential upside of 120.81%. As a group, “Consumer Staples Distribution & Retail” companies have a potential upside of 56.54%. Given Raia Drogasil’s stronger consensus rating and higher possible upside, equities analysts plainly believe Raia Drogasil is more favorable than its peers.

Dividends

Raia Drogasil pays an annual dividend of $0.04 per share and has a dividend yield of 1.7%. Raia Drogasil pays out 26.7% of its earnings in the form of a dividend. As a group, “Consumer Staples Distribution & Retail” companies pay a dividend yield of 3.7% and pay out 37.1% of their earnings in the form of a dividend.

Valuation & Earnings

This table compares Raia Drogasil and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Raia Drogasil $7.92 billion $232.27 million 15.70
Raia Drogasil Competitors $35.77 billion $834.68 million 17.52

Raia Drogasil’s peers have higher revenue and earnings than Raia Drogasil. Raia Drogasil is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Raia Drogasil Company Profile

(Get Free Report)

Raia Drogasil, now known as RD Saúde, is a Brazilian health and pharmacy retail company formed in 2011 through the merger of Droga Raia and Drogasil. It operates pharmacy stores under the Raia and Drogasil brands. The company sells prescription and over-the-counter medicines, personal care and beauty products, and other health and wellness goods. It serves customers across Brazil through its retail locations and digital channels, including online ordering and delivery. In addition to pharmacy retail, RD Saúde provides health-related services through its stores and digital platforms.

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.